CoChat

Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience

Open access
Calderon, Gerardo, Gonzalez-Izundegui, Daniel, Shan, Kuangda L., Garcia-Valencia, Oscar A., Cifuentes, Lizeth, Campos, Alejandro, Collazo-Clavell, Maria L., Shah, Meera, Hurley, Daniel L., Abu Lebdeh, Haitham S., Sharma, Mayank, Schmitz, Kristine, Clark, Matthew M., Grothe, Karen, Mundi, Manpreet S., Camilleri, Michael, Abu Dayyeh, Barham K., Hurtado Andrade, Maria D., Mokadem, Mohamad A., Acosta, Andres · 2022 · International Journal of Obesity

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Abstract

Randomized clinical trials have proven the efficacy and safety of Food and Drug Administration (FDA) approved anti-obesity medications (AOMs) for long-term use. It is unclear whether these outcomes can be replicated in real-world clinical practice where clinical complexities arise. The aim of this study was to evaluate the effectiveness and side effects of these medications in real-world multidisciplinary clinical practice settings. We reviewed the electronic medical records (EMR) of patients with obesity who were prescribed an FDA-approved AOM for long-term use in academic and community multidisciplinary weight loss programs between January 2016 and January 2020. We assessed percentage total body weight loss (%TBWL), metabolic outcomes, and side effect profile up to 24 months after AOM initiation. The full cohort consisted of 304 patients (76% women, 95.2% White, median age of 50 years old [IQR, 39–58]). The median follow-up time was 9.1 months [IQR, 4.2–14.1] with a median number of 3 visits [IQR, 2–4]. The most prescribed medication was phentermine/topiramate extended-release (ER) (51%), followed by liraglutide (26.3%), bupropion/naltrexone sustained-release (SR) (16.5%), and lorcaserin (6.2%). %TBWL was 5.0%, 6.8%, 9.3%, 10.3%, and 10.5% at 3, 6, 12, 18, and 24 months. 60.2% of the entire cohort achieved at least 5% TBWL. Overall, phentermine/topiramate-ER had the most robust weight loss response during follow-up, with the highest %TBWL at 12 months of 12.0%. Adverse events were reported in 22.4% of patients. Only 9% of patients discontinued the medication due to side effects. AOMs resulted in significant long-term weight loss, that was comparable to outcomes previously reported in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41366-021-01019-6

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity. 2019;27:591–602. · DOI · Paper page

Cited by

See all 52

Metadata

Authors
Calderon, G., Gonzalez-Izundegui, D., Shan, K. L., Garcia-Valencia, O. A., Cifuentes, L., Campos, A., Collazo-Clavell, M. L., Shah, M., Hurley, D. L., Abu Lebdeh, H. S., Sharma, M., Schmitz, K., Clark, M. M., Grothe, K., Mundi, M. S., Camilleri, M., Abu Dayyeh, B. K., Hurtado Andrade, M. D., Mokadem, M. A., & Acosta, A.
Affiliations
  • University of Iowa (US)
  • Mayo Clinic (US)
Corresponding author
  • Mokadem, Mohamad A.
  • Acosta, Andres
Venue
International Journal of Obesity
Published
2021-11-22
Volume
46
Issue
3
Pages
555-563
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
OpenAlex
W3217240228
Cited by
52
References
37
Citations by year
2026: 5 · 2025: 14 · 2024: 17 · 2023: 10 · 2022: 6
FWCI
4.78
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Obesity (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK114460)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
anti-obesity drugs, obesity, weight loss, liraglutide, lorcaserin, real-world effectiveness, adverse events, drug discontinuation, metabolic outcomes
MeSH terms
Topiramate, Adult, Female, Humans, Male, Middle Aged, Obesity, Phentermine, Weight Loss, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. https://app.cochat.ai/papers/10.1038/s41366-021-01019-6
The paper
Calderon, G., Gonzalez-Izundegui, D., Shan, K. L., Garcia-Valencia, O. A., Cifuentes, L., Campos, A., Collazo-Clavell, M. L., Shah, M., Hurley, D. L., Abu Lebdeh, H. S., Sharma, M., Schmitz, K., Clark, M. M., Grothe, K., Mundi, M. S., Camilleri, M., Abu Dayyeh, B. K., Hurtado Andrade, M. D., Mokadem, M. A., & Acosta, A. (2022). Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. International Journal of Obesity. https://doi.org/10.1038/s41366-021-01019-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.